CeO(2)-Azacrown Conjugate as a Nanoplatform for Combined Radiopharmaceuticals

This study is one of the first attempts to assess CeO(2) nanoparticles as a nanoplatform for radiopharmaceuticals with radionuclides. The process of functionalization using a bifunctional azacrown ligand is described, and the resulting conjugates are characterized by IR and Raman spectroscopy. Their...

Descripción completa

Detalles Bibliográficos
Autores principales: Khabirova, Sofia, Aleshin, Gleb, Plakhova, Tatiana, Zubenko, Anastasia, Shchukina, Anna, Fedorova, Olga, Averin, Aleksey, Belova, Ekaterina, Bazarkina, Elena, Kvashnina, Kristina, Kalmykov, Stepan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783244/
https://www.ncbi.nlm.nih.gov/pubmed/36558337
http://dx.doi.org/10.3390/nano12244484
Descripción
Sumario:This study is one of the first attempts to assess CeO(2) nanoparticles as a nanoplatform for radiopharmaceuticals with radionuclides. The process of functionalization using a bifunctional azacrown ligand is described, and the resulting conjugates are characterized by IR and Raman spectroscopy. Their complexes with (207)Bi show a high stability in medically relevant media, thus encouraging the further study of these conjugates in vivo as potential combined radiopharmaceuticals.

Ejemplares similares